Cancer cell detection device for the diagnosis of bladder cancer from urine.

Aminolevulinic Acid Biosensing Techniques Cystoscopy Humans Photosensitizing Agents Pilot Projects Urinary Bladder Neoplasms / diagnosis
Biofluids Biosensor Bladder cancer Cystoscopy EpCAM Hexaminolevulinic acid Immunocapture Microfluidic device Photodynamic diagnosis Plasma deposition PpIX fluorescence

Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
01 Jan 2021
Historique:
received: 02 10 2020
accepted: 05 10 2020
pubmed: 18 10 2020
medline: 1 5 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

Bladder cancer is common and has one of the highest recurrence rates. Cystoscopy, the current gold standard diagnosis approach, has recently benefited from the introduction of blue light assisted photodynamic diagnostic (PDD). While blue light cystoscopy improves diagnostic sensitivity, it remains a costly and invasive approach. Here, we present a microfluidic-based platform for non-invasive diagnosis which combines the principle of PDD with whole cell immunocapture technology to detect bladder cancer cells shed in patient urine ex vivo. Initially, we demonstrate with model cell lines that our non-invasive approach achieves highly specific capture rates of bladder cancer cells based on their Epithelial Cell Adhesion Molecule expression (>90%) and detection by the intensity levels of Hexaminolevulinic Acid-induced Protoporphyrin IX fluorescence. Then, we show in a pilot study that the biosensor platform successfully discriminates histopathologically diagnosed cancer patients (n = 10) from non-cancer controls (n = 25). Our platform can support the development of a novel non-invasive diagnostic device for post treatment surveillance in patients with bladder cancer and cancer detection in patients with suspected bladder cancer.

Identifiants

DOI: 10.1016/j.bios.2020.112699 PMID: 33068879
pubmed: 33068879
pii: S0956-5663(20)30688-6
doi: 10.1016/j.bios.2020.112699
pii:
doi:

Substances chimiques

Photosensitizing Agents 0
Aminolevulinic Acid 88755TAZ87

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112699

Informations de copyright

Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Auteurs

Melanie MacGregor (M)

Future Industry Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia. Electronic address: Melanie.Macgregor@unisa.edu.au.

Hanieh Safizadeh Shirazi (H)

Future Industry Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia; School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Kit Man Chan (KM)

School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Kola Ostrikov (K)

Future Industry Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia; School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Kym McNicholas (K)

Department of Renal Medicine, Flinders Medical Centre, Bedford Park, SA, 5042, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.

Alex Jay (A)

College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia; Department of Urology, Flinders Medical Centre, Bedford Park, SA, 5042, Australia.

Michael Chong (M)

College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia; Department of Urology, Flinders Medical Centre, Bedford Park, SA, 5042, Australia.

Alexander H Staudacher (AH)

Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, 5000, Australia; School of Medicine, University of Adelaide, SA, Adelaide, 5000, Australia.

Thomas D Michl (TD)

School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Aigerim Zhalgasbaikyzy (A)

School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Michael P Brown (MP)

Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, 5000, Australia; School of Medicine, University of Adelaide, SA, Adelaide, 5000, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, SA, Adelaide, 5000, Australia.

Moein Navvab Kashani (MN)

Future Industry Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia; South Australian Node of the Australian National Fabrication Facility, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Adam Di Fiore (A)

Motherson Innovations Australia, Lonsdale, SA, 5160, Australia.

Alex Grochowski (A)

Motherson Innovations Australia, Lonsdale, SA, 5160, Australia.

Stephen Robb (S)

Motherson Innovations Australia, Lonsdale, SA, 5160, Australia.

Simon Belcher (S)

Motherson Innovations Australia, Lonsdale, SA, 5160, Australia.

Jordan Li (J)

Department of Renal Medicine, Flinders Medical Centre, Bedford Park, SA, 5042, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.

Jonathan M Gleadle (JM)

Department of Renal Medicine, Flinders Medical Centre, Bedford Park, SA, 5042, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.

Krasimir Vasilev (K)

Future Industry Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia; School of Engineering, University of South Australia, Mawson Lakes, SA, 5095, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acide amino-lévulinique › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Techniques de biocapteur › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Procédures de chirurgie urologique › Cystoscopie › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Radiosensibilisants › Photosensibilisants › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Cancer cell detection device for the diagnosis...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Cancer cell detection device for the diagnosis...